Skip to main content
Top

Investigational New Drugs

Issue 4/2020

Content (30 Articles)

Breast Cancer PRECLINICAL STUDIES

Ibrutinib as a potential therapeutic option for HER2 overexpressing breast cancer – the role of STAT3 and p21

Chandra Bose Prabaharan, Allan Boyao Yang, Divya Chidambaram, Karthic Rajamanickam, Scott Napper, Meena Kishore Sakharkar

Gastric Cancer PRECLINICAL STUDIES

Identification of HGF as a novel target of miR-15a/16/195 in gastric cancer

Dongying Liu, Haiyang Zhang, Shaohua Ge, Dan Lin, Jiayi Han, Guoguang Ying, Yi Ba

Human Papillomavirus PRECLINICAL STUDIES

Benzothiazole derivative bearing amide moiety induces p53-mediated apoptosis in HPV16 positive cervical cancer cells

Arusha Modi, Meenakshi Singh, Gopichand Gutti, Ozasvi R. Shanker, Vinay Kumar Singh, Sunita Singh, Sushil Kumar Singh, Satyajit Pradhan, Gopeshwar Narayan

Open Access Lung Cancer PRECLINICAL STUDIES

Effects of salinomycin and niclosamide on small cell lung cancer and small cell lung cancer circulating tumor cell lines

Maximilian Hochmair, Barbara Rath, Lukas Klameth, Ernst Ulsperger, Christoph Weinlinger, Andreas Fazekas, Adelina Plangger, Robert Zeillinger, Gerhard Hamilton

Kidney Cancer PRECLINICAL STUDIES

The tumor suppressor NDRG2 cooperates with an mTORC1 inhibitor to suppress the Warburg effect in renal cell carcinoma

Xi’an Li, Guangdong Hou, Zheng Zhu, Fei Yan, Fuli Wang, Di Wei, Yu Zheng, Jiarui Yuan, Wanxiang Zheng, Geng Zhang, Ping Meng, Yan Guo, Xia Li, Libo Yao, Lan Shen, Jianlin Yuan

Lung Cancer PRECLINICAL STUDIES

Radiosensitizing effects of trabectedin on human A549 lung cancer cells and HT-29 colon cancer cells

Katrin Manda, Tina Präkelt, Tonja Schröder, Stephan Kriesen, Guido Hildebrandt

Melanoma PRECLINICAL STUDIES

A new series of acetohydroxamates shows in vitro and in vivo anticancer activity against melanoma

Gabriela C. Segat, Camila G. Moreira, Evelyn C. Santos, Melina Heller, Raquel C. Schwanke, Alexander V. Aksenov, Nicolai A. Aksenov, Dmitrii A. Aksenov, Alexander Kornienko, Rodrigo Marcon, João B. Calixto

Open Access Piperazine PRECLINICAL STUDIES

Synthesis and cellular effects of novel 1,3,5-triazine derivatives in DLD and Ht-29 human colon cancer cell lines

Agnieszka Wróbel, Beata Kolesińska, Justyna Frączyk, Zbigniew J. Kamiński, Anna Tankiewicz-Kwedlo, Justyna Hermanowicz, Robert Czarnomysy, Dawid Maliszewski, Danuta Drozdowska

PRECLINICAL STUDIES

Discovery and evaluation of Atopaxar hydrobromide, a novel JAK1 and JAK2 inhibitor, selectively induces apoptosis of cancer cells with constitutively activated STAT3

Jingjie Sun, Yuping Du, Xinxin Zhang, Zhuoya Wang, Yuxi Lin, Qiaoling Song, Xiao Wang, Jihui Guo, Shanshan Li, Jing Nan, Jinbo Yang

Chronic Myeloid Leukemia PRECLINICAL STUDIES

Naked antisense double-stranded DNA oligonucleotide efficiently suppresses BCR-ABL positive leukemic cells

Toshimi Hoshiko, Yasushi Kubota, Takuya Akisawa, Tatsuro Watanabe, Kazuaki Tanigawara, Junichi Yano, Shinya Kimura

Bladder Carcinoma PRECLINICAL STUDIES

7-Chloroquinoline-1,2,3-triazoyl carboxamides induce cell cycle arrest and apoptosis in human bladder carcinoma cells

Mariana S. Sonego, Natália V. Segatto, Lucas Damé, Mariana Fronza, Carolina B. Gomes, Thais Larré Oliveira, Fabiana Kömmling Seixas, Lucielli Savegnago, Kyle M. Schachtschneider, Diego Alves, Tiago Collares

Molecular Imaging PRECLINICAL STUDIES

Therapeutic efficacy and imaging assessment of the HER2-targeting chemotherapy drug ZHER2:V2-pemetrexed in lung adenocarcinoma Xenografts

Jingya Han, Yan Zhao, Xinming Zhao, Tuo Ma, Tiancheng Hao, Jiahui Liu, Zhaoqi Zhang, Jingmian Zhang, Jianfang Wang

Glioblastoma PRECLINICAL STUDIES

Matteucinol, isolated from Miconia chamissois, induces apoptosis in human glioblastoma lines via the intrinsic pathway and inhibits angiogenesis and tumor growth in vivo

Ana Gabriela Silva, Viviane Aline O. Silva, Renato J. S. Oliveira, Allisson Rodrigues de Rezende, Rafael César Russo Chagas, Lúcia Pinheiro Santos Pimenta, Wanderson Romão, Hélio Batista Santos, Ralph Gruppi Thomé, Rui Manuel Reis, Rosy Iara Maciel de Azambuja Ribeiro

Open Access Urothelial Cancer PHASE I STUDIES

A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma

Shunji Takahashi, Motohide Uemura, Tomokazu Kimura, Yoshihide Kawasaki, Atsushi Takamoto, Akito Yamaguchi, Amal Melhem-Bertrandt, Elaina M. Gartner, Takashi Inoue, Rio Akazawa, Takeshi Kadokura, Toshiki Tanikawa

Open Access Solid Tumor PHASE I STUDIES

A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors

Markus Joerger, Anastasios Stathis, Yannis Metaxas, Dagmar Hess, Mara Mantiero, Michael Mark, Matthias Volden, Thomas Kaindl, Marc Engelhardt, Patrice Larger, Heidi Lane, Peter Hafner, Nicole Levy, Silvia Stuedeli, Cristiana Sessa, Roger von Moos

Panitumumab PHASE I STUDIES

A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer

Rachel Goodwin, Derek Jonker, Eric Chen, Hagen Kennecke, Michael Cabanero, Ming-Sound Tsao, Michael Vickers, Caryn Bohemier, Howard Lim, Heather Ritter, Dongsheng Tu, Lesley Seymour

Open Access Pharmacokinetics PHASE I STUDIES

Mass balance and metabolite profiling of 14C-guadecitabine in patients with advanced cancer

Jeroen Roosendaal, Hilde Rosing, Luc Lucas, Abadi Gebretensae, Alwin D. R. Huitema, Marloes G. van Dongen, Jos H. Beijnen, Aram Oganesian

Pharmacokinetics PHASE I STUDIES

Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2)

Ruud van der Noll, Agnes Jager, Joo Ern Ang, Serena Marchetti, Marja W. J. Mergui-Roelvink, Johann S. de Bono, Martijn P. Lolkema, Maja J. A. de Jonge, Diane A. van der Biessen, Andre T. Brunetto, Hendrik-Tobias Arkenau, Ilian Tchakov, Jos H. Beijnen, Jacques De Grève, Jan H. M. Schellens

Pharmacokinetics PHASE I STUDIES

Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1)

Ruud van der Noll, Agnes Jager, Joo Ern Ang, Serena Marchetti, Marja W. J. Mergui-Roelvink, Martijn P. Lolkema, Maja J. A. de Jonge, Diane A. van der Biessen, Andre T. Brunetto, Hendrik-Tobias Arkenau, Ilian Tchakov, Jos H. Beijnen, Johann S. de Bono, Jan H. M. Schellens

Radiotherapy PHASE I STUDIES

Epigallocatechin-3-gallate mouthwash protects mucosa from radiation-induced mucositis in head and neck cancer patients: a prospective, non-randomised, phase 1 trial

Wanqi Zhu, Hui Mei, Li Jia, Hanxi Zhao, Xiaolin Li, Xiangjiao Meng, Xianguang Zhao, Ligang Xing, Jinming Yu

Glioblastoma PHASE I STUDIES

A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study

Sarah Lapointe, Warren Mason, Mary MacNeil, Craig Harlos, Roger Tsang, Joana Sederias, H. Artee Luchman, Samuel Weiss, John P. Rossiter, Dongsheng Tu, Lesley Seymour, Martin Smoragiewicz

Pharmacokinetics PHASE I STUDIES

A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer

Johanna C. Bendell, Helge G. Bischoff, Jimmy Hwang, Hans Christian Reinhardt, Thomas Zander, Xuejing Wang, Scott Hynes, Celine Pitou, Robert Campbell, Philip Iversen, Daphne L. Farrington, Katherine Bell-McGuinn, Michael Thomas

Solid Tumor PHASE I STUDIES

A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors

Albiruni R. Abdul Razak, Wilson H. Miller Jr, Geoffrey L. Uy, Steven Blotner, Anne-Marie Young, Brian Higgins, Lin-Chi Chen, Lia Gore

PHASE I STUDIES

Factors affecting symptom presentation in an early-phase clinical trials clinic patient population

Goldy C. George, Tito R. Mendoza, Eucharia C. Iwuanyanwu, Meryna Manandhar, Solmaz F. Afshar, Sarina A. Piha-Paul, Apostolia Tsimberidou, Aung Naing, Charles S. Cleeland, David S. Hong

Open Access Solid Tumor PHASE I STUDIES

Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors

Toshihiko Doi, Nobuaki Matsubara, Akira Kawai, Norifumi Naka, Shunji Takahashi, Hiroji Uemura, Noboru Yamamoto

NSCLC SHORT REPORT

Osimertinib in a patient with non-small cell lung cancer and renal failure undergoing hemodialysis: a case report

Atsushi Matsunashi, Daichi Fujimoto, Kazutaka Hosoya, Kei Irie, Shoji Fukushima, Keisuke Tomii

Endocrine Cancer SHORT REPORT

Prolonged response to 177Lu-DOTATATE therapy of a bone marrow infiltration in a refractory thymic neuro endocrine tumor

Anne Ségolène Cottereau, Léopoldine Bricaire, Jennifer Arrondeau, Amina Dechmi, Françoise Montravers, Romain Coriat, Jerome Clerc, Lionel Groussin, Florence Tenenbaum

Open Access Thrombosis SHORT REPORT

Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors

Yosuke Ando, Takahiro Hayashi, Reiko Sugimoto, Seira Nishibe, Kaori Ito, Kenji Kawada, Yoshiaki Ikeda, Shigeki Yamada, Kazuyoshi Imaizumi

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine